ImClone Reports Promising Erbitux First-Line Colorectal Cancer Results
This article was originally published in The Pink Sheet Daily
Executive Summary
Company will present data from the Phase III CRYSTAL study at ASCO in June.
You may also be interested in...
FDA Panel Views On PFS Endpoint For Avastin Could Impact Fate Of Other First-Line Cancer Drugs
Panel’s rejection of Genentech sBLA for first-line breast cancer despite meeting endpoint of progression-free survival leaves Wall Street wondering if same fate will befall ImClone/Bristol’s Erbitux in colon cancer.
FDA Panel Views On PFS Endpoint For Avastin Could Impact Fate Of Other First-Line Cancer Drugs
Panel’s rejection of Genentech sBLA for first-line breast cancer despite meeting endpoint of progression-free survival leaves Wall Street wondering if same fate will befall ImClone/Bristol’s Erbitux in colon cancer.
Amgen’s Colorectal Cancer Program Proceeding Despite Vectibix PACCE Failure
Company halts the Phase IIIb dual biologics study after an interim analysis showed greater benefit in the control arm and increased toxicity in the arm including Vectibix.